Table 2.

Previous therapies for PsO

Treatment
Topical treatment, n, (%)
Patients with at least one type of topical treatment	90 (89.1%)
Not available	11 (10.9%)
Main reason for discontinuation (n = 90)
Not achieving skin clearance	16 (17.8%)
Patient decision	4 (4.4%)
Side effects	4 (4.4%)
Other	19 (21.1%)
Not available	72 (80.0%)
Biological and/or systemic treatments, n, (%)
Patients with at least one type of biological and/or systemic treatment	90 (89.1%)
Not available	11 (10.9%)
Main reason for discontinuation (n = 90)
Loss of response	44 (48.9%)
No response	43 (47.8%)
Toxicity	33 (36.7%)
Physician decision due to reasons other than lack of effectiveness and toxicity	11 (12.2%)
Patient decision	4 (4.4%)
Other	2 (2.2%)
Not available	17 (18.9%)
Other therapies, n, (%)
Patients with at least one type of other therapy	32 (31.7%)
Not available	69 (68.3%)
Type of other therapy (in ≥ 4 patients)
Phototherapy	32 (100%)
PUVA	8 (25%)
UVB	23 (71.9%)
Main reason for discontinuation (n = 32)
No response	8 (25.0%)
Loss of response	8 (25%)
Patient decision	4 (12.5%)
Physician decision due to reasons other than lack of effectiveness and toxicity	3 (9.4%)
Toxicity	1 (3.1%)
Other	9 (28.1%)
Not available	8 (25.0%)

More than one reason for discontinuation per patient could be selected